论文部分内容阅读
PTG[4’-去甲基鬼臼毒9-(4,6-0-硫茂甲基-β-D-吡喃葡萄糖甙)]系一种半合成的鬼臼毒衍生物。 PTG 对实验性白血病 L1210有效,生命延长率超过500%,有60%患鼠长期存活。特别值得注意的是,对脑部接种的 L1210细胞有抑制作用。其作用原理可能是影响纺锤体的形成或阻止细胞从分裂的早前期进入分裂,属于细胞周期特异性药物。对实验性白血病 L1210的最佳给药方案为接种后第1,5,
PTG [4’-demethylphosporic acid 9-(4,6-0-thiomethyl-β-D-glucopyranoside)] is a semi-synthetic podophyllotoxin derivative. PTG is effective against experimental leukemia L1210, with a life extension rate of more than 500%, and 60% of the affected mice have long-term survival. Of particular note is the inhibition of brain-inoculated L1210 cells. Its principle of action may be to influence the formation of the spindle or to prevent cells from entering the division from the early stage of division, which is a cell cycle-specific drug. The optimal dosing regimen for experimental leukemia L1210 is No. 1 and No. 5 after inoculation.